Logo of plospathPLoS PathogensSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)View this Article
PLoS Pathog. Jul 2010; 6(7): e1001005.
Published online Jul 22, 2010. doi:  10.1371/journal.ppat.1001005
PMCID: PMC2908548

Quasispecies Theory and the Behavior of RNA Viruses

Marianne Manchester, Editor

Abstract

A large number of medically important viruses, including HIV, hepatitis C virus, and influenza, have RNA genomes. These viruses replicate with extremely high mutation rates and exhibit significant genetic diversity. This diversity allows a viral population to rapidly adapt to dynamic environments and evolve resistance to vaccines and antiviral drugs. For the last 30 years, quasispecies theory has provided a population-based framework for understanding RNA viral evolution. A quasispecies is a cloud of diverse variants that are genetically linked through mutation, interact cooperatively on a functional level, and collectively contribute to the characteristics of the population. Many predictions of quasispecies theory run counter to traditional views of microbial behavior and evolution and have profound implications for our understanding of viral disease. Here, we discuss basic principles of quasispecies theory and describe its relevance for our understanding of viral fitness, virulence, and antiviral therapeutic strategy.

Introduction

The rapid evolution of RNA viruses complicates the management of chronic infections and the control of emerging infectious agents [1][3]. The ongoing global AIDS pandemic and the resurgence of influenza highlight the difficulties associated with these genetically labile pathogens [4][6]. RNA viruses have also been responsible for recent sporadic epidemics of emerging and reemerging viral diseases including dengue, West Nile fever, and Ebola [7], [8]. Because of their high mutation rates, these viruses are moving targets for therapeutic intervention and frequently develop resistance to vaccines and antiviral drugs [9]. A clearer understanding of viral evolutionary dynamics and its relationship to virulence and drug resistance may facilitate the development of more effective therapeutics.

The evolutionary dynamics of RNA viruses are complex and their high mutation rates, rapid replication kinetics, and large population sizes present a challenge to traditional population genetics [10]. Quasispecies theory is a mathematical framework that was initially formulated to explain the evolution of life in the “precellular RNA world [11].” It builds on classical population genetics, but seeks to explore the consequences of error-prone replication and near-infinite population sizes for genome evolution [12], [13]. More recently, quasispecies theory has been used to describe the evolutionary dynamics of RNA viruses, and many of its predictions have been validated experimentally in model systems [2], [14], [15]. Some of these observations challenge more traditional views of evolution and have profound implications for the control and treatment of viral diseases.

Here we explain basic aspects of quasispecies theory, describe key experiments that define “quasispecies effects,” and highlight how these results may shape our view of viral pathogenesis, antiviral drug development, and vaccine design. We will stress three clinically relevant principles. First, the fitness of a particular virus sequence may be determined more by its freedom to mutate into related sequences than by its own replicative capacity. Second, many viruses operate near a threshold of “error catastrophe” and may be combated by increasing their replication error rates. Third, increasing the fidelity of genome replication may paradoxically attenuate viruses.

Error-Prone Replication and Viral Quasispecies

Most viruses encode enzymes responsible for replicating their DNA or RNA genomes. The intrinsic error rate, or fidelity, of the replicase determines the mutation rate for that virus and the range of genetic variation upon which natural selection can act. Viral RNA polymerases exhibit characteristically low fidelity with measured mutation rates of roughly 10−4 mutations per nucleotide copied, which is orders of magnitude greater than those of nearly all DNA-based viruses and organisms [10], [15], [16]. Given the large population sizes observed in both experimental and natural infections, it is estimated that every possible point mutation and many double mutations are generated with each viral replication cycle and may be present within the population at any time [17]. Because RNA viruses exist as swarms of similar variants that are continuously regenerated by mutation of related sequences, our ability to predict the outcome of an infection or a therapeutic intervention from studies of isolated clones is limited. Even a defined molecular clone will quickly transform into a collection of related sequences when introduced into cells. This collection is the quasispecies and is organized around a master sequence [12].

The genetic organization of populations is often depicted using the concept of sequence space, a geometric representation of all possible sequences where physical distance reflects genetic similarity. For example, a given viral genome will undergo replication and generate hundreds of progeny that differ at roughly one position (Figure 1). Subsequent rounds of replication will generate a more complex mutant distribution with variants lying farther away from each other in sequence space. This ensemble of mutants forms a “cloud” of variants, or quasispecies, in which mutation generates a swarm of candidate genomes that is pruned by natural selection. According to population genetics, the frequency of a given variant in a population is closely approximated by its ability to survive and reproduce—its fitness. In quasispecies formulations, where mutation rates are elevated, frequency is also subject to the probability that the variant will be generated de novo by mutation of its neighbors in sequence space [12]. In RNA viruses, the contribution of mutation to genotype frequency is significant, and variants are “coupled” in sequence space [18]. That is, a low fitness variant can be maintained at a higher than expected frequency because it is coupled to a well-represented, higher fitness genotype in sequence space. The phenomenon of mutational coupling is one of the defining characteristics of a quasispecies, as it places individual mutants within a functional network of variants [2].

Figure 1
RNA viruses exist as a quasispecies.

Viral populations evolve within a fitness landscape where the “ground level” is a representation of the range of genotypes in sequence space. The “altitude” at any given location is the fitness associated with that particular genotype. The environment and its selective pressures determine the contours of the corresponding landscape, and adaptation to an environment involves a mutational walk from one point in the fitness landscape to another (Figure 2A). In quasispecies theory, a network of mutationally coupled variants will span the corresponding peaks and valleys of the fitness landscape. A fast replicating population well suited to a given environment will inhabit a high and narrow peak in the fitness landscape, while a less fit but more genetically diverse population will occupy a lower, broader one.

Figure 2
The fitness landscape and survival of the flattest.

A viral quasispecies, then, is a cloud of diverse variants that are genetically linked through mutation, interact cooperatively on a functional level, and collectively contribute to the characteristics of the population. The unit of selection is the population as a whole, and the nature of the functional interactions among genetically distinct variants is therefore of critical importance to pathogenesis in infected hosts. These effects and their biomedical implications are described below.

The Problem of Fitness and Survival of the Flattest

Mutation and selection are the most fundamental processes in evolution. In Darwinian evolution, natural selection acts on existing genetic variation to optimize fitness. Conceptually, fitness refers to how well a given organism “fits” into its environment, often reflected in how well it survives and reproduces [19]. In experimental settings, precise fitness measurements are paramount, and virologists typically use replicative capacity as a surrogate for fitness [20]. While replication is useful as a first approximation, other factors such as immune escape, transmissibility, and cellular tropism are important components of fitness in the dynamic host environment [21]. Furthermore, because quasispecies theory adds the complexity of mutant networks, we must incorporate a population-based model into our fitness definition.

Measuring the fitness of individual variants within a population may misrepresent the fitness of a quasispecies. Early experiments with vesicular stomatitis virus (VSV) established that high fitness variants could be suppressed to low levels within a complex population [22]. Conversely, longitudinal studies of dengue virus isolates have identified defective clones that are stably maintained at a high frequency in the population [23]. Further consideration of the fitness landscape model may explain these paradoxical results (Figure 2B). Consider two populations, generated from either a fast replicator or a slower one. At low mutation rates, the fast replicator will triumph because its progeny are genetically identical and generated more quickly. In the fitness landscape, this population occupies a tall, narrow peak, where there is little genotypic diversity and maximal fitness. In RNA viruses, elevated mutation rates mean that a fast replicator will give rise to genetically diverse progeny, many of which are significantly less fit than the parent. Quasispecies theory predicts that slower replicators will be favored if they give rise to progeny that are on average more fit; these populations occupy short, flat regions of the fitness landscape [18]. This effect, termed survival of the flattest, has been observed in digital organisms, bacteriophages, and VSV [24][28]. Flat quasispecies accept mutation without a corresponding effect on fitness, and these mutationally robust populations form a large, selectively neutral network of variants in sequence space. While neutral mutations do not change the corresponding phenotype, they may have epistatic effects on subsequent mutations and redraw the genotype–phenotype map [29].

A flat quasispecies with an expansive mutant repertoire can explore vast regions of sequence space without consequence and is poised to adapt to rapid environmental change. This framework may explain many observed phenomena with direct clinical relevance. Arboviruses must successfully adapt to insect and mammalian hosts and their associated fitness landscapes. A quasispecies that occupies a broad, flat region of sequence space could access neutral networks and local fitness peaks in either environment. Similarly, retrospective studies of primary HIV isolates suggest that HIV could be moving to a flatter and less fit region of sequence space [20], [30][32]. In the case of influenza, detailed antigenic mapping of the hemagglutinin protein suggests that interpandemic strains remain antigenically stable for years despite genetic drift and evolve over a neutral region of sequence space. This steady accumulation of genetic diversity is punctuated by epochal shifts in antigenicity [33]. Though this adaptive process occurs on the interhost level over a long time scale, it highlights the importance of “flatness” in viral evolution.

Error Catastrophe

Given their high mutation rates, it is not surprising that many discussions of RNA virus evolution focus on the relationship between genetic diversity and adaptability. While it is clear that RNA viruses have the capacity to quickly explore large regions of sequence space, genome size and selective constraints place significant limitations on the amount of diversity that is actually expressed [34]. Most RNA virus genomes are relatively small and contain either overlapping reading frames or sequences that serve both coding and structural functions. Similarly, coding mutations that mediate escape from host immune surveillance may compromise protein function. In VSV, for example, approximately 60% of spontaneous mutations are deleterious [35]. Evolutionary theory would suggest that the short-term cost of mutation is balanced by the long-term benefit of adaptability in the face of a dynamic environment [36], [37].

Quasispecies theory accepts this trade-off, and proposes an upper limit to mutation rate, the “error threshold” (Figure 3A). According to Eigen's original formulations, a quasispecies can remain at equilibrium despite a high mutation rate [38], [39]. Small increases in mutation rate will upset this balance as the master sequence itself disappears and meaningful genetic information is lost in an avalanche of errors. Because Eigen compared this process to chemical phase transitions, it has been termed “mutational meltdown.” It is now clear that many RNA viruses replicate near the error threshold. Early studies with VSV showed that chemical mutagens generally reduced viral infectivity, and studies with poliovirus clearly demonstrated that mutagenic nucleoside analogs push viral populations to extinction [40][43]. The effect is dramatic—a 4-fold increase in mutation rate resulted in a 95% reduction in viral titer. Others have found similar results with lymphocytic choriomeningitis virus (LCMV) and foot and mouth disease virus (FMDV) [44][48]. The lethal mutagenesis of viral populations is perhaps the most important implication of the error threshold.

Figure 3
Mutant distributions and the error threshold.

Recent work on host cell restriction of retroviral infection suggests that lethal mutagenesis is a natural form of antiviral defense [49]. The cytidine deaminase APOBEC3G was initially identified as a protein targeted by the HIV Vif protein during replication [50]. Humans have 11 APOBEC proteins that edit cellular messages by converting cytosine bases to uracil. Subsequent work demonstrated that APOBEC proteins could induce lethal mutagenesis of HIV through widespread deamination of the HIV genome during reverse transcription, and highly mutagenized HIV genomes with signatures of deamination have been observed in patients [51][56]. This mechanism appears to be evolutionarily conserved and active against hepatitis B virus, simple retroviruses, and endogenous retroelements [57]. While mutation-independent activities have also been identified, it is clear that APOBEC-mediated lethal mutagenesis is a critical cellular defense against RNA viruses. The fact that these pathogens replicate close to the error threshold makes them particularly sensitive to slight increases in mutational load (Figure 3A).

These observations suggest that lethal mutagenesis could be an effective therapeutic strategy for RNA virus infections [58]. Ribavirin, a nucleoside with broad antiviral activity, has attracted considerable interest, and can induce lethal mutagenesis of Hantaan virus and poliovirus [42], [43], [59]. While ribavirin is used clinically for the treatment of both respiratory syncytial virus and hepatitis C virus, it has pleiotropic effects, and its mechanism of action in these infections is unclear [60]. Another mutagen, 5-fluorouracil, is licensed as a chemotherapeutic agent, and its antiviral activity against LCMV in animal models may predict efficacy for other arenaviruses, such as Lassa fever [61], [62]. Spurred by these results, Loeb and colleagues have identified a number of nucleoside analogs capable of inducing the lethal mutagenesis of HIV [63][65].

While these results are encouraging, much work needs to be done before lethal mutagenesis can be considered as a quasispecies-inspired therapeutic strategy. Some have argued for a distinction between lethal mutagenesis and error catastrophe, and have suggested, on theoretical grounds, that the above experiments do not show a true phase transition with loss of a master sequence. Indeed, careful studies of lethal mutagenesis by Lowenstein and colleagues have shown an imperfect correlation between mutational load and population extinction [46]. Pre-extinction populations exhibit marked heterogeneity in both the location and number of mutations per genome. The dynamics of extinction are further complicated by the observation that highly mutagenized genomes can accelerate extinction by interfering with the replication of their less mutated brethren [47], [66]. In that case, a mutagenized population would collapse without the genetic melting of an error catastrophe. While these discrepancies may reflect the gap between mathematical theory and biological complexity, the distinction could have “real world” implications. Mutation is a double-edged sword, and adaptive evolution can be accelerated at high mutation rates [67]. Absent a true mutational meltdown, a large pre-extinction population could serve as a reservoir for novel mutants that mediate antiviral resistance or immune escape [68][70].

The potential for mutagen resistance is another important concern. In principle, a virus could evolve biochemical resistance to nucleosides either by excluding the drug from its active site or by lowering its intrinsic error rate (see below). Quasispecies theory suggests that viruses could also achieve resistance by moving to flatter regions of the fitness landscape, where the density of neutral mutations is higher. Combination therapy with mutagens and traditional antivirals may minimize the probability of mutagenic escape, and work in the FMDV system is encouraging [71], [72]. The safety of nucleoside analogs is a major concern that is largely unexplored. Drug concentrations in the above studies were often in the millimolar range, and mutagenic nucleosides with a wider therapeutic index are clearly needed. Given the potential for off-target effects on host cell polymerases, therapy would likely need to be short term—a problem for HIV, where eradication of the latent reservoir is critical.

Mutation Rate, Virulence, and Attenuation

Evolutionary theory predicts that high mutation rates are favored in a dynamic environment, and viral error rates may have been optimized by natural selection [36], [37]. For RNA viruses, low replicative fidelity generates a diverse population of variants. While these variants are generally less fit, they may quickly dominate if a sudden change in environment, such as immune pressure, shifts the corresponding fitness landscape. Conversely, a homogeneous population, generated by high replicative fidelity, would lack this flexibility and might be less successful in the dynamic host environment.

Recent work by two groups in the poliovirus system provides experimental support for this model. Drawing on experience with ribavirin and lethal mutagenesis, they hypothesized that a mutant with a low mutation rate would be less sensitive to lethal mutagenesis and resistant to ribavirin. Both groups sought to isolate ribavirin resistant mutants from a poliovirus quasispecies and recovered a variant with a single amino acid substitution in the viral polymerase (3DpolG64S) [73], [74]. This mutant was relatively resistant to lethal mutagenesis, and assays for selectable markers indicated that the G64S population had a lower mutation rate and exhibited less genetic diversity (Figure 3B) [73], [75], [76]. While wild-type and G64S quasispecies replicated with similar kinetics, the former was more “fit” in direct competition assays [75], [76]. Together, these data suggested that high mutation rates confer an evolutionary advantage to RNA viruses.

The G64S quasispecies was markedly attenuated in a transgenic mouse model for poliovirus infection; the high fidelity variants were less successful at accessing the central nervous system (CNS), the site of disease [76]. Importantly, virulence was determined in large part by the diversity of the coinfecting population (Figure 4). When brain-derived polioviruses were introduced as members of the genetically homogeneous G64S population, they were not able to invade the CNS. In contrast, brain-derived viruses readily accessed the CNS when the population inoculum contained a wild-type distribution of variants. These results suggest that quasispecies diversity, rather than the selection of individual variants, correlates with enhanced virulence [76]. The demonstration of cooperative interactions among mutants in a population established the relevance of quasispecies theory to studies of viral pathogenesis. Vignuzzi and colleagues extended this model and hypothesized that the observed attenuation of the high fidelity variants could be exploited for vaccine design [77]. Focusing on the G64 position, they engineered several high fidelity mutants that were markedly attenuated in mice. These viruses stimulated high titers of neutralizing antibody in immunized mice, and provided lasting protection against subsequent lethal challenge with wild-type virus.

Figure 4
Population diversity is a virulence determinant.

This work shows how quasispecies theory and its predictions can lead to the rational development of live, attenuated vaccines. Because variants with low mutation rates would be less likely to revert to wild type in a vaccinee, attenuation should be a stable phenotype and increase the safety of candidate vaccines. Caution is warranted, however, since the error rates of the high fidelity variants are still orders of magnitude greater than those of DNA viruses. It is also unclear whether reducing mutation rate will similarly affect the adaptability and virulence of other RNA viruses. Further work in other systems is clearly needed before this work can be translated into new vaccines [78], [79]. As in the case of lethal mutagenesis, the modulation of fidelity offers an opportunity to use mutation rate as a therapeutic strategy for the control of viral disease.

Perspectives on the Future

Quasispecies theory has had a profound influence on virology, and experiments with model RNA viruses have validated many of its predictions. Considerably less is known about how its population-based models apply to the evolutionary behavior of RNA viruses in infected hosts, and it will be challenging to translate them to the complex reality of viral infection in patients. The initial studies pose as many questions as they answer. What is the best measure of viral fitness in a dynamic population? How can we use a fitness landscape model to understand selection pressure in vivo, where many such landscapes coexist? Do the principles of mutational robustness and survival of the flattest determine the behavior of populations in the host ecosystem? How does population diversity influence pathogenesis? What are the mechanisms by which variants or subpopulations cooperate, and does this have implications for coinfection?

While early forays into complex experimental systems have provided tantalizing results, much more work is needed in this area if quasispecies theory is to be translated from bench to bedside. Improved assays for characterizing viral populations are critical, and the advent of ultra high throughput, or “deep” sequencing, is particularly exciting. Several groups have used this technology to explore the complexity of mutant spectra in clinical samples from HIV- and HBV-infected patients, although the sequencing error rate presents certain limitations for studies of RNA as opposed to DNA viruses [80][82]. Discerning quasispecies structure from the wealth of sequencing data presents significant computational challenges as well, since current techniques are underdeveloped and do not permit us to determine which mutations are linked on the same genome. Complementary approaches, such as molecular barcoding, will also be required if we are to understand how the mutant spectrum changes temporally or spatially within an infected host [83]. Finally, future drug and vaccine studies will need to be carried out in well-defined animal models, as subtle differences can have a significant impact on experimental outcome. Despite these obstacles, we are confident that quasispecies theory will soon move out of the laboratory and begin to influence the control and treatment of viral disease.

Acknowledgments

We thank Steve Deeks, Harry Lampiris, Joseph Wong, and Paul Baum for comments on the manuscript.

Footnotes

The authors have declared that no competing interests exist.

This work was supported by grants from the NIAID to RA (R01 AI36178 and R01 AI40085) and ASL (K08 AI081754-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Domingo E, Baranowski E, Ruiz-Jarabo CM, Martin-Hernandez AM, Saiz JC, et al. Quasispecies structure and persistence of RNA viruses. Emerg Infect Dis. 1998;4:521–527. [PMC free article] [PubMed]
2. Domingo E, Martin V, Perales C, Grande-Perez A, Garcia-Arriaza J, et al. Viruses as quasispecies: biological implications. Curr Top Microbiol Immunol. 2006;299:51–82. [PubMed]
3. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet. 2008;9:267–276. [PubMed]
4. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385. [PubMed]
5. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–2615. [PubMed]
6. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet. 2004;5:52–61. [PubMed]
7. Fields BN, Knipe DM, Howley PM. Fields' virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. p. 2 v. (xix, 3091, I-3086 p.).
8. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10:S110–121. [PubMed]
9. Gerrish PJ, Garcia-Lerma JG. Mutation rate and the efficacy of antimicrobial drug treatment. Lancet Infect Dis. 2003;3:28–32. [PubMed]
10. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, et al. Rapid evolution of RNA genomes. Science. 1982;215:1577–1585. [PubMed]
11. Eigen M. Selforganization of matter and the evolution of biological macromolecules. Naturwissenschaften. 1971;58:465–523. [PubMed]
12. Biebricher CK, Eigen M. What is a quasispecies? Curr Top Microbiol Immunol. 2006;299:1–31. [PubMed]
13. Eigen M. Viral quasispecies. Sci Am. 1993;269:42–49. [PubMed]
14. Domingo E, Sabo D, Taniguchi T, Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell. 1978;13:735–744. [PubMed]
15. Batschelet E, Domingo E, Weissmann C. The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene. 1976;1:27–32. [PubMed]
16. Steinhauer DA, Holland JJ. Rapid evolution of RNA viruses. Annu Rev Microbiol. 1987;41:409–433. [PubMed]
17. Vignuzzi M, Stone JK, Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005;107:173–181. [PubMed]
18. Wilke CO. Quasispecies theory in the context of population genetics. BMC Evol Biol. 2005;5:44. [PMC free article] [PubMed]
19. Orr HA. Fitness and its role in evolutionary genetics. Nat Rev Genet. 2009;10:531–539. [PMC free article] [PubMed]
20. Quinones-Mateu ME, Arts EJ. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol. 2006;299:83–140. [PubMed]
21. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151–178. [PubMed]
22. de la Torre JC, Holland JJ. RNA virus quasispecies populations can suppress vastly superior mutant progeny. J Virol. 1990;64:6278–6281. [PMC free article] [PubMed]
23. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science. 2006;311:236–238. [PubMed]
24. Wilke CO, Wang JL, Ofria C, Lenski RE, Adami C. Evolution of digital organisms at high mutation rates leads to survival of the flattest. Nature. 2001;412:331–333. [PubMed]
25. Burch CL, Chao L. Evolvability of an RNA virus is determined by its mutational neighbourhood. Nature. 2000;406:625–628. [PubMed]
26. Codoñer FM, Darós J-A, Solé RV, Elena SF. The fittest versus the flattest: experimental confirmation of the quasispecies effect with subviral pathogens. PLoS Pathog. 2006;2:e136. doi: 10.1371/journal.ppat.0020136. [PMC free article] [PubMed]
27. Sanjuan R, Cuevas JM, Furio V, Holmes EC, Moya A. Selection for Robustness in Mutagenized RNA Viruses. PLoS Genet. 2007;3:e93. doi: 10.1371/journal.pgen.0030093. [PMC free article] [PubMed]
28. Quer J, Hershey CL, Domingo E, Holland JJ, Novella IS. Contingent neutrality in competing viral populations. J Virol. 2001;75:7315–7320. [PMC free article] [PubMed]
29. Draghi JA, Parsons TL, Wagner GP, Plotkin JB. Mutational robustness can facilitate adaptation. Nature. 2010;463:353–355. [PMC free article] [PubMed]
30. Ariën KK, Troyer RM, Gali Y, Colebunders RL, Arts EJ, et al. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. AIDS. 2005;19:1555–1564. [PubMed]
31. Richman DD. Antiviral drug resistance. Antiviral Res. 2006;71:117–121. [PubMed]
32. Rolland M, Brander C, Nickle DC, Herbeck JT, Gottlieb GS, et al. HIV-1 over time: fitness loss or robustness gain? Nat Rev Microbiol. 2007;5:1–2. [PubMed]
33. Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science. 2006;314:1898–1903. [PubMed]
34. Overbaugh J, Bangham CR. Selection forces and constraints on retroviral sequence variation. Science. 2001;292:1106–1109. [PubMed]
35. Sanjuán R, Moya A, Elena SF. The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci USA. 2004;101:8396–8401. [PMC free article] [PubMed]
36. Elena SF, Sanjuán R. Adaptive value of high mutation rates of RNA viruses: separating causes from consequences. J Virol. 2005;79:11555–11558. [PMC free article] [PubMed]
37. Holmes EC. Error thresholds and the constraints to RNA virus evolution. Trends Microbiol. 2003;11:543–546. [PubMed]
38. Biebricher CK, Eigen M. The error threshold. Virus Res. 2005;107:117–127. [PubMed]
39. Eigen M. Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA. 2002;99:13374–13376. [PMC free article] [PubMed]
40. Holland JJ, Domingo E, de la Torre JC, Steinhauer DA. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol. 1990;64:3960–3962. [PMC free article] [PubMed]
41. Lee CH, Gilbertson DL, Novella IS, Huerta R, Domingo E, et al. Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J Virol. 1997;71:3636–3640. [PMC free article] [PubMed]
42. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A. 2001;98:6895–6900. [PMC free article] [PubMed]
43. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6:1375–1379. [PubMed]
44. Domingo E, Pariente N, Airaksinen A, Gonzaĺez-Lopez C, Sierra S, et al. Foot-and-mouth disease virus evolution: exploring pathways towards virus extinction. Curr Top Microbiol Immunol. 2005;288:149–173. [PubMed]
45. Grande-Perez A, Gomez-Mariano G, Lowenstein PR, Domingo E. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol. 2005;79:10451–10459. [PMC free article] [PubMed]
46. Grande-Perez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC. Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A. 2005;102:4448–4452. [PMC free article] [PubMed]
47. Grande-Perez A, Sierra S, Castro MG, Domingo E, Lowenstein PR. Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A. 2002;99:12938–12943. [PMC free article] [PubMed]
48. Sierra S, Dávila M, Lowenstein PR, Domingo E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol. 2000;74:8316–8323. [PMC free article] [PubMed]
49. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond, B, Biol Sci. 2009;364:675–687. [PMC free article] [PubMed]
50. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. [PubMed]
51. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003;113:803–809. [PubMed]
52. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424:99–103. [PubMed]
53. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003;424:94–98. [PMC free article] [PubMed]
54. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A. 1994;91:3092–3096. [PMC free article] [PubMed]
55. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005;79:1975–1980. [PMC free article] [PubMed]
56. Janini M, Rogers M, Birx DR, McCutchan FE. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol. 2001;75:7973–7986. [PMC free article] [PubMed]
57. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci. 2007;32:118–128. [PubMed]
58. Anderson JP, Daifuku R, Loeb LA. Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol. 2004;58:183–205. [PubMed]
59. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol. 2003;77:481–488. [PMC free article] [PubMed]
60. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008;28:1332–1343. [PubMed]
61. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC. Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology. 2003;308:37–47. [PubMed]
62. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20–26. [PubMed]
63. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, et al. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA. 1999;96:1492–1497. [PMC free article] [PubMed]
64. Loeb LA, Mullins JI. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res Hum Retroviruses. 2000;16:1–3. [PubMed]
65. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res. 2005;67:1–9. [PubMed]
66. Gonzalez-Lopez C, Arias A, Pariente N, Gomez-Mariano G, Domingo E. Preextinction viral RNA can interfere with infectivity. J Virol. 2004;78:3319–3324. [PMC free article] [PubMed]
67. Springman R, Keller T, Molineux I, Bull J. Evolution at a High Imposed Mutation Rate: Adaptation Obscures the Load in Phage T7. Genetics 2009 [PMC free article] [PubMed]
68. Gifford RJ, Rhee S-Y, Eriksson N, Liu TF, Kiuchi M, et al. Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance. AIDS. 2008;22:717–725. [PMC free article] [PubMed]
69. Pillai SK, Wong JK, Barbour JD. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology. 2008;5:26. [PMC free article] [PubMed]
70. Mulder LCF, Harari A, Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA. 2008;105:5501–5506. [PMC free article] [PubMed]
71. Pariente N, Sierra S, Airaksinen A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res. 2005;107:183–193. [PubMed]
72. Pariente N, Airaksinen A, Domingo E. Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol. 2003;77:7131–7138. [PMC free article] [PubMed]
73. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem. 2005;280:25706–25716. [PMC free article] [PubMed]
74. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A. 2003;100:7289–7294. [PMC free article] [PubMed]
75. Pfeiffer JK, Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog. 2005;1:e11. doi: 10.1371/journal.ppat.0010011. [PMC free article] [PubMed]
76. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439:344–348. [PMC free article] [PubMed]
77. Vignuzzi M, Wendt E, Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med. 2008;14:154–161. [PubMed]
78. Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. 2006;344:9–16. [PubMed]
79. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990;63:353–362. [PubMed]
80. Bushman FD, Hoffmann C, Ronen K, Malani N, Minkah N, et al. Massively parallel pyrosequencing in HIV research. Aids. 2008;22:1411–1415. [PMC free article] [PubMed]
81. Eriksson N, Pachter L, Mitsuya Y, Rhee SY, Wang C, et al. Viral population estimation using pyrosequencing. PLoS Comput Biol. 2008;4:e1000074. doi: 10.1371/journal.pcbi.1000074. [PMC free article] [PubMed]
82. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275–1285. [PMC free article] [PubMed]
83. Mazurkiewicz P, Tang CM, Boone C, Holden DW. Signature-tagged mutagenesis: barcoding mutants for genome-wide screens. Nat Rev Genet. 2006;7:929–939. [PubMed]

Articles from PLoS Pathogens are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...